

## Anatara completes Placement and announces Share Purchase Plan to raise up to a further \$750,000

---

### Key Highlights:

- Anatara has received firm commitments to raise \$1.67 million through the proposed issue of 11,133,333 shares at \$0.15 per share (**Placement**) to new and existing sophisticated and institutional investors. It is proposed that the Placement will be issued in two tranches. The second tranche will be subject to Shareholder approval at the 2020 Annual General Meeting (**AGM**)
- In parallel, Anatara Lifesciences announces a Share Purchase Plan (**SPP**) to raise up to \$750,000 through the issue of ordinary shares at the price detailed in this Announcement
- Funds raised from the Placement and the SPP will be used to progress a clinical study of Anatara's GaRP in irritable bowel syndrome (**IBS**)

MELBOURNE, 21 October 2020: Anatara Lifesciences Limited ('**Anatara**' or '**Company**') (ASX: ANR) is pleased to announce it has received firm commitments for a two trrenched Placement. In addition, Anatara will launch a share purchase plan offer (**SPP**) to existing shareholders to raise up to an additional \$750,000 (before costs).

### Placement

Anatara has received firm commitments to raise \$1.67 million through the proposed issue of 11,133,333 shares at \$0.15 per share (**Placement**) from professional and sophisticated investors through the proposed issue of a total of 11,133,333 new fully paid ordinary shares in the Company (**Placement Shares**). It is proposed that the Placement Shares will be issued as follows:

- 7,466,667 Placement Shares will be issued on or around 28 October 2020 subject to receipt of funds on 27 October 2020 (**Tranche 1 Placement Shares**);
- 3,666,666 Placement Shares will be issued on or around 3 December 2020 (following the approval of Shareholders at the 2020 AGM) subject to receipt of funds on 2 December 2020 (**Tranche 2 Placement Shares**).

The issue price of \$0.15 per Placement Share represents a discount of 25% to the last closing price of Anatara shares.

The allotment of the Tranche 1 Placement Shares will be issued within Anatara's 15% placement capacity under ASX Listing Rule 7.1. The Tranche 2 Placement Shares are subject to Shareholder approval at the 2020 Annual General Meeting of Anatara, scheduled for 26 November 2020.

The Placement Shares will rank equally with existing fully paid shares in Anataara. As far as the Company is aware, no New Shares are agreed to be issued in the Placement to a related party or otherwise to any person referred to in Listing Rule 10.11.

Taylor Collison Limited was the Lead Manager and Bookrunner to the Placement.

The Placement was not underwritten.

### **Share Purchase Plan**

Anataara will give eligible shareholders an opportunity to subscribe for new fully paid ordinary shares (**SPP Shares**) in Anataara by way of an SPP.

The issue price of the SPP shares will be at least 80% of the VWAP of the ordinary shares in Anataara calculated over the last 5 days on which sales in ordinary shares were recorded before the day on which the issue of SPP Shares will be made, subject to a floor price of \$0.15 per SPP Share.

Under the SPP, each shareholder who held shares in Anataara at 7:00pm (Melbourne time), on Tuesday 20 October 2020 and who has a registered address in Australia or New Zealand will be entitled to acquire up to \$30,000 of SPP Shares without brokerage. The SPP will raise up to a capped amount of \$750,000 (before costs).

Full details of the SPP (including details of any scale back in the event of oversubscription) will be set out in the SPP Offer Booklet which is expected to be released to ASX and despatched to eligible shareholders on 28 October 2020.

### **Use of funds**

The funds raised from the Placement and SPP will be used to progress a clinical study of Anataara's GaRP in irritable bowel syndrome (IBS). In parallel with execution of its human health development plans, the Company has prioritised removing barriers to out-licensing Detach® through progression of challenge trials for newly developed formulations for piglets (in-feed) and for poultry. The Company anticipates renewed interest in partnering Detach® upon successful completion of challenge trials.



## Key dates

The key dates for the Placement and SPP are as follows:

Record Date (for the SPP)	7PM, 20 October 2020
Announcement of Placement and SPP and recommencement of trading of Shares on the ASX	21 October 2020
Settlement of Tranche 1 Placement Shares	27 October 2020
Issue of Tranche 1 Placement Shares	28 October 2020
Despatch of SPP Offer Booklet	28 October 2020
SPP Opens	28 October 2020
SPP closes	11 November 2020
Results of SPP announced to the ASX	16 November 2020
Issue of Shares under the SPP	18 October 2020
2020 Annual General Meeting	26 November 2020
Settlement of Tranche 2 Placement Shares	2 December 2020
Issue of Tranche 2 Placement Shares	3 December 2020

Anatara reserves the right, subject to the Corporations Act, ASX Listing Rules and other applicable laws, to vary any or all of the dates and times of the placement and SPP without prior notice, including extending the SPP or to withdraw the SPP without prior notice. Any extension of the closing date of the SPP will have a consequential effect on the issue date of SPP Shares under the SPP.

Anatara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)



**For more information please contact:**

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

### **About Anatara Lifesciences Ltd**

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

### **Disclaimer**

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

**Anatara Lifesciences Limited**

**Registered Office**

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

**Administration and R&D**

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

